CF PharmTech, Inc.

长风药业股份有限公司

02652.HK

Develops, manufactures and commercializes inhalation drugs for respiratory diseases in China, with products approved by NMPA and FDA. Main product CF017, a budesonide inhalation suspension, accounted for about 16% of China's budesonide inhalation market by sales volume in 2024, per F&S.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Distribution model
• Single product, business line or region
• Government or SOE customers and tenders
• Pricing policy and price changes
• Particular sales arrangements
• Capacity and utilisation
• Losses and path to profitability
• Decline in revenue or profit
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Investments and fair-value assets
• Adverse change after the track record
• Non-IFRS measures and adjustments
• Material share-based payments